studying-pancreatic-cancer-stem-cell-characteristics-for-developing

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Pancreatic ductal adenocarcinoma (PDAC) contains a subset of exclusively tumorigenic cancer stem cells (CSCs) which have been shown to drive tumor ...

Queen Mary University of London

There is a strong rationale for sequencing targeted therapy in metastatic clear cell renal cancer. However the timing of the switch and the best agent to switch to remains unclear. Randomized data currently are supportive of the sequence of axitinib, followed by everolimus in those patients in which first-line vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy fails. Everolimus is also justified in the second-line setting, and the overall survival data for sorafenib in VEGF TKI resistant disease is impressive. A degree of cross-resistance appears to exist between all these current agents and has resulted in a drive toward the development of new therapies with novel modes of action.

Shanthini Crusz

Center for Stem Cells in Cancer & Ageing,
Barts Cancer Institute,
Center for Stem Cells in Cancer & Ageing, Barts Cancer Institute

Queen Mary University of London

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Shanthini Crusz

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Center for Stem Cells in Cancer & Ageing,Barts Cancer Institute,Center for Stem Cells in Cancer & Ageing, Barts Cancer Institute

Queen Mary University of London

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Center for Stem Cells in Cancer & Ageing,
Barts Cancer Institute,
Center for Stem Cells in Cancer & Ageing, Barts Cancer Institute